Neurogene entered into an underwriting agreement to sell 3,500,000 shares at $30.00 per share and pre-funded warrants for 666,666 shares at $29.999999 each. The underwriters exercised in full a 30-day option to purchase an additional 624,999 shares on July 1, 2026. Net proceeds are expected to be approximately $134.8 million, and the offering is expected to close on July 2, 2026. The pre-funded warrants are immediately exercisable, subject to beneficial ownership limits.
Agreement details:
- Agreement type: Underwriting agreement for public offering of common stock and pre-funded warrants
- Counterparty: Leerink Partners, Stifel, and Guggenheim Securities, as representatives of the underwriters
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: At will
- Reason: Raise capital to fund operations into 2029
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.